185 related articles for article (PubMed ID: 9915408)
1. Renal cell carcinoma: management of advanced disease.
Figlin RA
J Urol; 1999 Feb; 161(2):381-6; discussion 386-7. PubMed ID: 9915408
[TBL] [Abstract][Full Text] [Related]
2. Advanced renal cell carcinoma.
Redman BG; Chang AE
Curr Treat Options Oncol; 2000 Dec; 1(5):417-22. PubMed ID: 12057149
[TBL] [Abstract][Full Text] [Related]
3. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.
Figlin RA; Pierce WC; Kaboo R; Tso CL; Moldawer N; Gitlitz B; deKernion J; Belldegrun A
J Urol; 1997 Sep; 158(3 Pt 1):740-5. PubMed ID: 9258071
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy for renal cell carcinoma.
Motzer RJ; Russo P
J Urol; 2000 Feb; 163(2):408-17. PubMed ID: 10647643
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF
Cancer; 2009 May; 115(10 Suppl):2298-305. PubMed ID: 19402060
[TBL] [Abstract][Full Text] [Related]
7. Management of metastatic renal cell carcinoma: current trends.
Mohammed A; Shergill I; Little B
Expert Rev Mol Diagn; 2009 Jan; 9(1):75-83. PubMed ID: 19099350
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF; Atkins MB
Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
[TBL] [Abstract][Full Text] [Related]
9. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
10. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
11. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
12. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
13. Adoptive cellular therapy.
Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
[TBL] [Abstract][Full Text] [Related]
14. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Harshman LC; Srinivas S
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749
[TBL] [Abstract][Full Text] [Related]
15. The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.
Figlin RA; Abi-Aad AS; Belldegrun A; deKernion JB
Semin Oncol; 1991 Oct; 18(5 Suppl 7):102-7. PubMed ID: 1719641
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
17. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
Bex A; Horenblas S; de Gast GC
Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy of renal cell carcinoma. With special emphasis on therapy of the elderly patient].
Heinzer H; Huland E; Huland H
Urologe A; 2003 Nov; 42(11):1450-2. PubMed ID: 14624342
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of metastatic renal cell cancer.
Fishman M; Seigne J
Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
[TBL] [Abstract][Full Text] [Related]
20. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
